Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Spontaneous bacterial peritonitis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Spontaneous bacterial peritonitis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Spontaneous bacterial peritonitis strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Read →
Refractory ascites Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Refractory ascites Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
Explore the 2026 Refractory ascites indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Read →
Minimal hepatic encephalopathy Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Minimal hepatic encephalopathy Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Minimal hepatic encephalopathy strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Read →
Crigler-Najjar syndrome type 2 Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Crigler-Najjar syndrome type 2 Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Crigler-Najjar syndrome type 2 strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Read →
Progressive familial intrahepatic cholestasis type 5 Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Progressive familial intrahepatic cholestasis type 5 Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Progressive familial intrahepatic cholestasis type 5 strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built.
Read →
Congenital portosystemic shunt Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Congenital portosystemic shunt Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Congenital portosystemic shunt strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Read →
Classic galactosemia Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Classic galactosemia Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Classic galactosemia strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Read →
Progressive familial intrahepatic cholestasis type 4 Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Progressive familial intrahepatic cholestasis type 4 Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Progressive familial intrahepatic cholestasis type 4 strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built.
Read →
Alagille syndrome liver disease Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Alagille syndrome liver disease Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Alagille syndrome liver disease strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Read →
Polycystic liver disease Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Polycystic liver disease Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Polycystic liver disease strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Read →
Caroli syndrome Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Caroli syndrome Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
Explore the 2026 Caroli syndrome indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Read →
Peliosis hepatis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Peliosis hepatis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
Explore the 2026 Peliosis hepatis indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Read →